Timo Korjamo
- Oncology top 10%
- Molecular Biology
- Pharmacology top 2%
- Pharmaceutical Science top 2%
- Pediatrics, Perinatology and Child Health top 10%
- Co-authors
- Jukka MönkkönenAki T. HeikkinenAntti PertovaaraAntti HassinenAri KoivistoSeppo AuriolaJuni PalmgrenAri Tolonen
- Topics
- Drug Transport and Resistance Mechanisms (9 papers)Pharmacogenetics and Drug Metabolism (8 papers)Analytical Chemistry and Chromatography (4 papers)
- Journals
- Journal of Clinical OncologyBritish Journal of CancerJournal of Pharmacology and Experimental Therapeutics
- Partner nations
- FinlandGermanyUnited Kingdom
In The Last Decade
Timo Korjamo
29 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 109
- Oncology 373
- Molecular Biology 310
- Pharmacology 170
- Pharmaceutical Science 145
- Pediatrics, Perinatology and Child Health 134
Countries citing papers authored by Timo Korjamo
This map shows the geographic impact of Timo Korjamo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Korjamo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Korjamo more than expected).
Fields of papers citing papers by Timo Korjamo
This network shows the impact of papers produced by Timo Korjamo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Korjamo. The network helps show where Timo Korjamo may publish in the future.
Co-authorship network of co-authors of Timo Korjamo
This figure shows the co-authorship network connecting the top 25 collaborators of Timo Korjamo. A scholar is included among the top collaborators of Timo Korjamo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Korjamo. Timo Korjamo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 9 | |
| 3 | 4 | |
| 4 | 7 | |
| 5 | 71 | |
| 6 | 76 | |
| 7 | 16 | |
| 8 | 37 | |
| 9 | 9 | |
| 10 | 16 | |
| 11 | 22 | |
| 12 | 7 | |
| 13 | 39 | |
| 14 | 199 | |
| 15 | 26 | |
| 16 | 31 | |
| 17 | 25 | |
| 18 | 106 | |
| 19 | 18 | |
| 20 | 31 |
About Timo Korjamo
Timo Korjamo is a scholar working on Pharmacology, Pharmaceutical Science and Sensory Systems, having authored 29 papers that have together received 1.0k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Analytical Chemistry and Chromatography (4 papers). The work is most often cited by research in Pharmaceutical Science (145 citations), Pharmacology (170 citations) and Sensory Systems (89 citations). Timo Korjamo has collaborated with scholars based in Finland, Germany and United Kingdom. Frequent co-authors include Jukka Mönkkönen, Aki T. Heikkinen, Antti Pertovaara, Antti Hassinen, Ari Koivisto, Seppo Auriola, Juni Palmgren, Ari Tolonen, Miia Turpeinen and Paavo Honkakoski. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.